Journal of Endocrinological Investigation

, Volume 41, Issue 5, pp 583–590 | Cite as

Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients

  • A. D. Genazzani
  • K. Shefer
  • D. Della Casa
  • A. Prati
  • A. Napolitano
  • A. Manzo
  • G. Despini
  • T. Simoncini
Original Article



To evaluate the efficacy of alpha-lipoic acid (ALA) administration on hormonal and metabolic parameters of obese PCOS patients.


A group of 32 obese PCOS patients were selected after informed consent. 20 patients referred to have first grade relatives with diabetes type I or II. Hormonal and metabolic parameters as well as OGTT were evaluated before and after 12 weeks of ALA integrative administration (400 mg per os every day).


ALA administration significantly decreased insulin, glucose, BMI and HOMA index. Hyperinsulinemia and insulin response to OGTT decreased both as maximal response (Δmax) and as AUC. PCOS with diabetes relatives showed the decrease also of triglyceride and GOT. Interestingly in all PCOS no changes occurred on all hormonal parameters involved in reproduction such as LH, FSH, and androstenedione.


ALA integrative administration at a low dosage as 400 mg daily improved the metabolic impairment of all PCOS patients especially in those PCOS with familiar diabetes who have a higher grade of risk of NAFLD and predisposition to diabetes.


PCOS Hyperinsulinemia Familiar diabetes Alpha-lipoic-acid Insulin resistance 


Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

The study was performed in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards

Informed consent

Informed consent was obtained from all patients participating in the study.


  1. 1.
    Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH et al (2012) Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 97:28–38CrossRefPubMedGoogle Scholar
  2. 2.
    Genazzani AD, Despini G, Santagni S, Prati S, Rattighieri E, Chierchia E, Simoncini T (2014) Effects of a combination of alpha lipoic acid and myo-inositol on insulin dynamics in overweight/obese patients with PCOS. Endocrinol Metab Synd 3:3. CrossRefGoogle Scholar
  3. 3.
    Genazzani AD, Ricchieri F, Lanzoni C (2010) Use of metformin in the treatment of polycystic ovary syndrome. Womens Health (Lond) 6:577–593CrossRefGoogle Scholar
  4. 4.
    Genazzani AD (2016) Inositol as putative integrative treatment for PCOS. Reprod BioMed Online 33:770–780CrossRefPubMedGoogle Scholar
  5. 5.
    Mario FM, Graff SK, Spritzer PM (2017) Habitual physical activity is associated with improved anthropometric and androgenic profile in PCOS: a cross-sectional study. J Endocrinol Invest 40:377–384CrossRefPubMedGoogle Scholar
  6. 6.
    Genazzani AD, Chierchia E, Rattighieri E, Santagni S, Casarosa E et al (2010) Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS. Gynecol Endocrinol 26:684–689CrossRefPubMedGoogle Scholar
  7. 7.
    Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O (2004) Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 81:114–119CrossRefPubMedGoogle Scholar
  8. 8.
    Lord JM, Flight IH, Norman RJ (2003) Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327:951–953CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, Apridonidze T, Iuorno MJ et al (2006) Altered d-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 29:300–305CrossRefPubMedGoogle Scholar
  10. 10.
    Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM (2008) Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 24:139–144CrossRefPubMedGoogle Scholar
  11. 11.
    Genazzani AD, Santagni S, Rattighieri E, Chierchia E, Despini G, Marini G, Prati A, Simoncini T (2014) Modulatory role of d-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol 30:438–443CrossRefPubMedGoogle Scholar
  12. 12.
    Dinicola S, Chiu TTY, Unfer V, Carlomagno G, Bizzarri M (2014) The rationale of the myo-inositol and d-chiro-inositol combined treatment for polycystic ovary syndrome. J Clin Pharmacol 20:1–14Google Scholar
  13. 13.
    Lee WJ, Song KH, Koh EH, Won JC, Kim HS et al (2005) Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun 332:885–891CrossRefPubMedGoogle Scholar
  14. 14.
    Shen QW, Zhu MJ, Tong J, Ren J, Du M (2007) Ca2+/calmodulindependent protein kinase kinase is involved in AMP-activated protein kinase activation by alpha-lipoic acid in C2C12 myotubes. Am J Physiol Cell Physiol 293:C1395–C1403CrossRefPubMedGoogle Scholar
  15. 15.
    Gomes MB, Negrato CA (2014) Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetol Metab Syndr 6(1):80. doi: 10.1186/1758-5996-6-80
  16. 16.
    Scaramuzza A, Giani E, Radaelli F, Ungheri S, Macedoni M, Giudici V, Bosetti A, Ferrari M, Zuccotti GV (2015) Alpha-Lipoic acid and antioxidant diet help to improve endothelial dysfunction in adolescents with type 1 diabetes: a pilot study. J Diabetes Res. (Article ID 474561) Google Scholar
  17. 17.
    Masharani U, Gjerde C, Evans JL, Youngren JF, Goldfine ID (2010) Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J Diabetes Sci Technol 4(2):359–364CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Madeira IR, Carvalho CN, Gazolla FM, de Matos HJ, Borges MA et al (2008) Cut-off point for Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) index established from Receiver Operating Characteristic (ROC) curve in the detection of metabolic syndrome in overweight prepubertal children. Arq Bras Endocrinol Metabol 52:1466–1473CrossRefPubMedGoogle Scholar
  19. 19.
    Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E et al (2012) Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol 28:969–973CrossRefPubMedGoogle Scholar
  20. 20.
    Genazzani AD, Petraglia F, Benatti R, Montanini V, Algeri I et al (1991) Luteinizing hormone (LH) secretory burst duration is independent from LH, prolactin, or gonadal steroid plasma levels in amenorrheic women. J Clin Endocrinol Metab 72:1220–1225CrossRefPubMedGoogle Scholar
  21. 21.
    Geloneze B, Vasques AC, Stabe CF, Pareja JC, Rosado LE et al (2009) HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras Endocrinol Metabol 53:281–287CrossRefPubMedGoogle Scholar
  22. 22.
    Genazzani AD, Ricchieri F, Prati A, Santagni S, Chierchia E, Rattighieri E, Campedelli A, Simoncini T, Artini PG (2012) Differential insulin response to myo-inositol administration in obese PCOS patients. Gynecol Endocrinol 28:969–973CrossRefPubMedGoogle Scholar
  23. 23.
    Morikawa T, Yasuno R, Wada H (2001) Do mammalian cells synthesize lipoic acid? Identification of a mouse cDNA encoding a lipoic acid synthase located in mitochondria. FEBS Lett 498:16–21CrossRefPubMedGoogle Scholar
  24. 24.
    Padmalayam I, Hasham S, Saxena U, Pillarisetti S (2009) Lipoic acid synthase (LASY): a novel role in inflammation, mitochondrial function, and insulin resistance. Diabetes 58:600–608CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P et al (2002) Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51:2074–2081CrossRefPubMedGoogle Scholar
  26. 26.
    Macut D, Božić-Antić I, Bjekić-Macut J, Tziomalos K (2017) Polycystic ovary syndrome and nonalcoholic fatty liver disease. Eur J Endocrinol 177:R145–R158CrossRefPubMedGoogle Scholar
  27. 27.
    Bae JC, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW, Park SW, Kim SW (2011) Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 34:727–729. CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Artini PG, Di Berardino OM, Papini F et al (2013) Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol 29:375–379CrossRefPubMedGoogle Scholar
  29. 29.
    Kamenov Z, Kolarov G, Gateva A, Carlomagno G, Genazzani AD (2015) Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol Endocrinol 31(2):131–135CrossRefPubMedGoogle Scholar
  30. 30.
    Cianci A, Panella M, Fichera M, Falduzzi C, Bartolo M, Caruso S (2015) d-chiro-inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS. Gynecol Endocrinol 31(6):483–486CrossRefPubMedGoogle Scholar
  31. 31.
    Thomas RM, Nechamen CA, Mazurkiewicz JE, Ulloa-Aguirre A, Dias JA (2011) The adapter protein APPL1 links FSH receptor to inositol 1,4,5-trisphosphate production and is implicated in intracellular Ca(2+) mobilization. Endocrinology 152:1691–1701CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2017

Authors and Affiliations

  • A. D. Genazzani
    • 1
  • K. Shefer
    • 1
  • D. Della Casa
    • 1
  • A. Prati
    • 1
  • A. Napolitano
    • 1
  • A. Manzo
    • 1
  • G. Despini
    • 1
  • T. Simoncini
    • 2
  1. 1.Department of Obstetrics and Gynecology, Gynecological Endocrinology CenterUniversity of Modena and Reggio EmiliaModenaItaly
  2. 2.Department of Obstetrics and GynecologyUniversity of PisaPisaItaly

Personalised recommendations